IP Library Granted Patent US 6,936,270
Granted Patent B2
US 6,936,270 · App. 10/139,143 · Granted Aug 30, 2005

Device and method for treating conditions of a joint

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 6,936,270
App. No.
10/139,143
Granted
Aug 30, 2005
Kind
B2
Abstract

A therapeutically effective compound is locally administered by associating the compound with a piece of orthopedic hardware that is implanted at an appropriate site within a body. The compound is adapted, such as through a sustained release device, to administer an effective dosage continuously over an extended period of time. The compound may be administered, for example, to a joint of a mammal by intraarticularly implanting a sustained release device to deliver the therapeutically effective compound within a synovial capsule of the joint, such that synovial fluid concentration of the compound is greater than plasma concentration of the compound. A wide range of orthopedic hardware, such as bone screws and staples, may be adapted to use in the systems described herein to provide treatment for a variety of medical conditions.

Claims (67)

1. A system comprising:

a bone screw attachable to a portion of a body, the bone screw including a head; and

a sustained release device formed in a chamber in the head, the sustained release device configured to release a compound having a therapeutic effect over an extended period of time.

2. The system of claim 1 wherein the bone screw is at least one of a cannulated bone screw and an interference bone screw.

3. A system comprising:

an orthopedic hardware component attachable to a portion of a body; and

a sustained release device threaded to the orthopedic hardware component such that the sustained release device is rotatable removable from and replaceable to the orthopedic hardware component, the sustained release device configured to release a compound having a therapeutic effect over an extended period of time.

4. The system of claim 3 wherein the sustained release device is a cap threaded to an outward projecting surface of the orthopedic hardware component.

5. The system of claim 3 wherein the sustained release device is a screw threaded to an inwardly projecting surface of the orthopedic hardware component.

6. A system comprising:

an orthopedic hardware component attachable to a portion of a body; and

a sustained release device removably associated with the orthopedic hardware component using an interference fit, the sustained release device configured to release a compound having a therapeutic effect over an extended period of time.

7. A system comprising:

an orthopedic hardware component attachable to a portion of a body and including a first suture eve; and

a sustained release device including a second suture eye, the sustained release device removably associated with the orthopedic hardware component using a suture through each of the first suture eye and the second suture eye, the sustained release device configured to release a compound having a therapeutic effect over an extended period of time.

8. The system of claim 6 or 7 , the orthopedic hardware component including a chamber, the sustained release device configured for placement in the chamber of the orthopedic hardware component.

9. A system comprising:

an orthopedic hardware component attachable to a portion of a body; and

a sustained release device associated with the orthopedic hardware component, the sustained release device configured to release a compound having a therapeutic effect over an extended period of time wherein the compound is a low-solubility compound.

10. The system of claim 9 wherein the compound comprises a matrix of an effective agent and a polymer that is permeable to the effective agent.

11. The system of claim 9 wherein the sustained release device includes an inner core containing the compound, the sustained release device further comprising a non-bioerodible polymer coating layer, the non-bioerodible polymer coating layer being permeable to the compound, wherein the non-bioerodible polymer coating layer covers the inner core and is essentially non-release rate limiting.

12. A system comprising:

an orthopedic hardware component attachable to a portion of a body; and

a sustained release device associated with the orthopedic hardware component, the sustained release device configured to release a compound having a therapeutic effect over an extended period of time wherein the compound comprises a soluble compound.

13. The system of claim 12 wherein the compound is surrounded by an outer layer that covers the compound and includes a first surface and a second surface, the first surface being substantially impermeable to the compound and the second surface being permeable to the compound and limiting a release rate of the compound.

14. The system of claim 1 , the compound including at least one of a steroid, an antibiotic, an anti-inflammatory drug, an antiproliferative compound, an antimyotic compound, an antimitotic compound, an antimetabolite compound, a pain-relieving drug, a corticosteroid, an angiostatic steroid, a non-steroidal anti-inflammatory agent, or a co-drug.

15. The system of claim 1 , the therapeutic effect including at least one of an anti-inflammatory effect, a pain-relief effect, an anesthetic effect, an immune suppressant effect, an antibiotic effect, an anti-viral effect, a cancer-fighting effect, an anti-cancer effect, an anti-proliferative effect, a cartilage-protecting effect, or an anti-scarring effect.

16. A method comprising:

attaching an orthopedic hardware component to a portion of a body wherein attaching the orthopedic hardware component further comprises driving a pin into a bone of the body;

providing a compound having a therapeutic effect;

associating the compound with the orthopedic hardware component; and

releasing the compound over an extended period of time.

17. A method comprising:

attaching an orthopedic hardware component to a portion of a body wherein attaching the orthopedic hardware component further comprises suturing the component to a soft tissue of the body;

providing a compound having a therapeutic effect;

associating the compound with the orthopedic hardware component; and

releasing the compound over an extended period of time.

18. A method comprising:

attaching an orthopedic hardware component to a portion of a body wherein the orthopedic hardware component includes at least one of a staple, a tack, a dart, a bolt, a washer, a plate, a prosthetic joint, a component of a prosthetic joint, an anchor, a pin, a wire, or a button;

providing a compound having a therapeutic effect;

associating the compound with the orthopedic hardware component; and

releasing the compound over an extended period of time.

19. A method comprising:

attaching an orthopedic hardware component to a portion of a body;

providing a compound having a therapeutic effect;

associating the compound with the orthopedic hardware component wherein associating the compound with the orthopedic hardware component further comprises removably attaching a sustained release device that includes the compound to the orthopedic hardware component using at least one of threads that rotatably engage the sustained release device to the orthopedic hardware component, an interference fit between the sustained release device and the orthopedic hardware component, a pin passing through the orthopedic hardware component and the sustained release device, or a suture passing between a suture eye of each one of the orthopedic hardware component and the sustained release device; and

releasing the compound over an extended period of time.

20. The method of claim 16 wherein the compound is a low-solubility compound, releasing the compound further comprising exposing the compound to a bodily fluid such that the compound dissolves into the bodily fluid.

21. The method of claim 16 wherein the compound is a high-solubility compound, releasing the compound further comprising exposing the compound to a bodily fluid through a membrane that limits a rate of release of the compound.

22. The method of claim 16 wherein the compound includes at least one of a steroid, an antibiotic, an anti-inflammatory drug, an antiproliferative compound, an antimyotic compound, an antimitotic compound, an antimetabolite compound, a pain-relieving drug, a corticosteroid, an angiostatic steroid, a non-steroidal anti-inflammatory agent, or a co-drug.

23. The method of claim 16 wherein the therapeutic effect includes at least one of an anti-inflammatory effect, a pain-relief effect, an anesthetic effect, an immune suppressant effect, an antibiotic effect, an anti-viral effect, a cancer-fighting effect, an anti-cancer effect, an anti-proliferative effect, a cartilage-protecting effect, or an anti-scarring effect.

24. The method of claim 16 wherein attaching the orthopedic hardware component comprises attaching the component within a synovial capsule of a joint, the compound including one or more treatments for at least one of osteoarthritis or rheumatoid arthritis.

25. The method of claim 17 wherein the compound is a low-solubility compound, releasing the compound further comprising exposing the compound to a bodily fluid such that the compound dissolves into the bodily fluid.

26. The method of claim 17 wherein the compound is a high-solubility compound, releasing the compound further comprising exposing the compound to a bodily fluid through a membrane that limits a rate of release of the compound.

27. The method of claim 17 wherein the compound includes at least one of a steroid, an antibiotic, an anti-inflammatory drug, an antiproliferative compound, an antimyotic compound, an antimitotic compound, an antimetabolite compound, a pain-relieving drug, a corticosteroid, an angiostatic steroid, a non-steroidal anti-inflammatory agent, or a co-drug.

28. The method of claim 17 wherein the therapeutic effect includes at least one of an anti-inflammatory effect, a pain-relief effect, an anesthetic effect, an immune suppressant effect, an antibiotic effect, an anti-viral effect, a cancer-fighting effect, an anti-cancer effect, an anti-proliferative effect, a cartilage-protecting effect, or an anti-scarring effect.

29. The method of claim 17 wherein attaching the orthopedic hardware component comprises attaching the component within a synovial capsule of a joint, the compound including one or more treatments for at least one of osteoarthritis or rheumatoid arthritis.

30. The method of claim 18 wherein the compound is a low-solubility compound, releasing the compound further comprising exposing the compound to a bodily fluid such that the compound dissolves into the bodily fluid.

31. The method of claim 18 wherein the compound is a high-solubility compound, releasing the compound further comprising exposing the compound to a bodily fluid through a membrane that limits a rate of release of the compound.

32. The method of claim 18 wherein the compound includes at least one of a steroid, an antibiotic, an anti-inflammatory drug, an antiproliferative compound, an antimyotic compound, an antimitotic compound, an antimetabolite compound, a pain-relieving drug, a corticosteroid, an angiostatic steroid, a non-steroidal anti-inflammatory agent, or a co-drug.

33. The method of claim 18 wherein the therapeutic effect includes at least one of an anti-inflammatory effect, a pain-relief effect, an anesthetic effect, an immune suppressant effect, an antibiotic effect, an anti-viral effect, a cancer-fighting effect, an anti-cancer effect, an anti-proliferative effect, a cartilage-protecting effect, or an anti-scarring effect.

34. The method of claim 18 wherein attaching the orthopedic hardware component comprises attaching the component within a synovial capsule of a joint, the compound including one or more treatments for at least one of osteoarthritis or rheumatoid arthritis.

35. The method of claim 19 wherein the compound is a low-solubility compound, releasing the compound further comprising exposing the compound to a bodily fluid such that the compound dissolves into the bodily fluid.

36. The method of claim 19 wherein the compound is a high-solubility compound, releasing the compound further comprising exposing the compound to a bodily fluid through a membrane that limits a rate of release of the compound.

37. The method of claim 19 wherein the compound includes at least one of a steroid, an antibiotic, an anti-inflammatory drug, an antiproliferative compound, an antimyotic compound, an antimitotic compound, an antimetabolite compound, a pain-relieving drug, a corticosteroid, an angiostatic steroid, a non-steroidal anti-inflammatory agent, or a co-drug.

38. The method of claim 19 wherein the therapeutic effect includes at least one of an anti-inflammatory effect, a pain-relief effect, an anesthetic effect, an immune suppressant effect, an antibiotic effect, an anti-viral effect, a cancer-fighting effect, an anti-cancer effect, an anti-proliferative effect, a cartilage-protecting effect, or an anti-scarring effect.

39. The method of claim 19 wherein attaching the orthopedic hardware component comprises attaching the component within a synovial capsule of a joint, the compound including one or more treatments for at least one of osteoarthritis or rheumatoid arthritis.

Assignments (8)
RELEASE OF SECURITY INTEREST Recorded Mar 14, 2022
From: CRG SERVICING LLC, AS ADMINISTRATIVE AGENT
To: EYEPOINT PHARMACEUTICALS, INC.; EYEPOINT PHARMACEUTICALS US, INC.; ICON BIOSCIENCE, INC.
Reel/Frame 059365/0112 →
CHANGE OF NAME Recorded Oct 22, 2019
From: PSIVIDA US, INC.
To: EYEPOINT PHARMACEUTICALS US, INC.
Reel/Frame 050796/0985 →
CHANGE OF NAME Recorded Apr 3, 2019
From: PSIVIDA INC.
To: PSIVIDA US, INC.
Reel/Frame 048787/0610 →
MERGER Recorded Apr 2, 2019
From: CONTROL DELIVERY SYSTEMS, INC.; PSIVIDA INC.
To: PSIVIDA INC.
Reel/Frame 048768/0796 →
RELEASE OF SECURITY INTEREST Recorded Feb 13, 2019
From: SWK FUNDING LLC, AS AGENT
To: PSIVIDA CORP.; PSIVIDA US, INC.; ICON BIOSCIENCE, INC.
Reel/Frame 048329/0136 →
SECURITY INTEREST Recorded Feb 13, 2019
From: EYEPOINT PHARMACEUTICALS, INC.; EYEPOINT PHARMACEUTICALS US, INC.; ICON BIOSCIENCE, INC.
To: CRG SERVICING LLC, AS ADMINISTRATIVE AGENT
Reel/Frame 048329/0045 →
SECURITY INTEREST Recorded Apr 5, 2018
From: PSIVIDA CORP.
To: SWK FUNDING LLC, AS AGENT
Reel/Frame 045848/0670 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 23, 2002
From: WATSON, DAVID A.; LA PORTE, RICHARD; ASHTON, PAUL; SMITH, THOMAS J.; CHEN, JIANBING
To: CONTROL DELIVERY SYSTEMS
Reel/Frame 013428/0060 →